Table 3 Assocition of lymphadenopathy with the expression of NF κβ and PIM2 genes in AML and ALL patients
Lymphadenopathy N (%) | No lymphadenopath N (%) | P value | |
|---|---|---|---|
PIM2 gene expression (in AML patients) | No. 7 (23.3%) | No. 23 (76.7%) | |
Mean±SD | 0.836±4.226 | 9.744±14.288 | 0.962 |
Range | 0.609-12.535 | 0.131-53.040 | |
NF-κβ expression (in AML patients) | |||
Mean±SD | 0.836±0.412 | 0.995±0.457 | 0.631 |
Range | 0.402-1.284 | 0.207-2.208 | |
PIM gene expression (in ALL patients) | No. 26 (86.7%) | No. 4 (13.3%) | |
Mean±SD | 7.090±22.555 | 0.369±0.195& | |
Range | 0.004-83.644 | 0.127-0.605 | |
NF-κβ gene expression (in ALL patients) | |||
Mean±SD | 2.437±2.198 | 4.384±2.769& | |
Range | 0.128-8.630 | 1.024-6.655 | |